Cargando…

Real-world use of sunitinib in Japanese patients with pancreatic neuroendocrine tumors: results from a post-marketing surveillance study

BACKGROUND: Sunitinib is approved for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNETs) in patients with unresectable, locally advanced or metastatic disease. Safety and efficacy data in Japanese patients are limited. We report outcomes from a post-marketing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sato, Kazuo, Toyoshima, Yasuharu, Moriyama, Shiho, Endo, Yutaka, Ito, Tetsuhide, Ohki, Emiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373178/ https://www.ncbi.nlm.nih.gov/pubmed/30413868 http://dx.doi.org/10.1007/s00280-018-3724-3

Ejemplares similares

Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study
por: Ito, Tetsuhide, et al.
Publicado: (2019)

Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumor
por: Komatsu, Yoshito, et al.
Publicado: (2015)

Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor
por: Ito, Tetsuhide, et al.
Publicado: (2013)

Real-world use of temsirolimus in Japanese patients with unresectable or metastatic renal cell carcinoma: recent consideration based on the results of a post-marketing, all-case surveillance study
por: Sugiyama, Shigeru, et al.
Publicado: (2020)

Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors
por: Hijioka, Masayuki, et al.
Publicado: (2014)

Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib
por: Jiménez-Fonseca, Paula, et al.
Publicado: (2018)

Everolimus for Advanced Pancreatic Neuroendocrine Tumours: A Subgroup Analysis Evaluating Japanese Patients in the RADIANT-3 Trial
por: Ito, Tetsuhide, et al.
Publicado: (2012)

Safety and Efficacy of Sunitinib in Patients with Unresectable Pancreatic Neuroendocrine Tumors
por: Wiedmann, Marcus W., et al.
Publicado: (2012)

Long-Term Safety and Effectiveness of Thyrotropin Alfa in Japanese Patients: A Post-Marketing Surveillance Study
por: Kanamori, Rie, et al.
Publicado: (2021)

Aflibercept with FOLFIRI in Japanese patients with metastatic colorectal cancer: results of a post-marketing surveillance
por: Watanabe, Jun, et al.
Publicado: (2022)

Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms
por: Daskalakis, Kosmas, et al.
Publicado: (2019)

Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study
por: Masui, Toshihiko, et al.
Publicado: (2020)

Use of cinacalcet and sunitinib to treat hypercalcaemia due to a pancreatic neuroendocrine tumor
por: Valdes-Socin, Hernan, et al.
Publicado: (2017)

Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors
por: Ito, Tetsuhide, et al.
Publicado: (2017)

Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison
por: Signorovitch, James, et al.
Publicado: (2013)

Surgery after sunitinib administration to improve survival of patients with advanced pancreatic neuroendocrine neoplasms
por: Murase, Yoshiki, et al.
Publicado: (2021)

Japanese Physicians’ Views on Drug Post-Marketing Surveillance
por: Maeda, Kazuki, et al.
Publicado: (2015)

Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors
por: Okamoto, Isamu, et al.
Publicado: (2010)

A Japanese Post-marketing Surveillance of Cetuximab (Erbitux(®)) in Patients with Metastatic Colorectal Cancer
por: Ishiguro, Megumi, et al.
Publicado: (2012)

Transformation of Nonfunctioning Pancreatic Neuroendocrine Carcinoma Cells into Insulin Producing Cells after Treatment with Sunitinib
por: Ohn, Jung Hun, et al.
Publicado: (2013)

Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib
por: Fazio, Nicola, et al.
Publicado: (2021)

Sapropterin for phenylketonuria: A Japanese post‐marketing surveillance study
por: Tamura, Mina, et al.
Publicado: (2022)

Long‐term safety and efficacy of lanreotide autogel in Japanese patients with neuroendocrine tumors: Final results of a phase II open‐label extension study
por: Ito, Tetsuhide, et al.
Publicado: (2020)

Phase I/II study of streptozocin monotherapy in Japanese patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors
por: Komoto, Izumi, et al.
Publicado: (2022)

Real-World Safety and Efficacy of Glycopyrronium Bromide in Japanese Patients with COPD: A 52-Week Post-Marketing Surveillance
por: Kato, Chihiro, et al.
Publicado: (2022)

The Current Strategy for Managing Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1
por: Niina, Yusuke, et al.
Publicado: (2012)

Effect of Golimumab Dose Escalation in Japanese Patients With Rheumatoid Arthritis: Post-Hoc Analysis of Post-Marketing Surveillance Data
por: Shimizu, Hirohito, et al.
Publicado: (2020)

All-case Japanese post-marketing surveillance of the real-world safety and efficacy of rituximab treatment in patients with refractory nephrotic syndrome
por: Kobayashi, Mana, et al.
Publicado: (2021)

Long-Term Observation of the Safety and Effectiveness of Enzyme Replacement Therapy in Japanese Patients with Pompe Disease: Results From the Post-marketing Surveillance
por: Nagura, Hitoshi, et al.
Publicado: (2019)

1-year outcomes of patients implanted with the Perceval sutureless valve: the Japanese post-marketing surveillance study
por: Niinami, Hiroshi, et al.
Publicado: (2023)

Correction to: Effect of Golimumab Dose Escalation in Japanese Patients With Rheumatoid Arthritis: Post-Hoc Analysis of Post-Marketing Surveillance Data
por: Shimizu, Hirohito, et al.
Publicado: (2020)

Safety and effectiveness of once-yearly zoledronic acid in Japanese osteoporosis patients: three-year post-marketing surveillance
por: Takada, Junichi, et al.
Publicado: (2023)

Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients
por: Akaza, Hideyuki, et al.
Publicado: (2015)

An Advanced Well-differentiated Pancreatic Neuroendocrine Carcinoma (NET-G3) Associated with Von Hippel-Lindau Disease
por: Miki, Masami, et al.
Publicado: (2018)

Characteristics of early-onset hematotoxicity of sunitinib in Japanese patients with renal cell carcinoma
por: Kato, Renpei, et al.
Publicado: (2017)

Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with unresectable urothelial carcinoma: a nation-wide post-marketing surveillance
por: Nishiyama, Hiroyuki, et al.
Publicado: (2023)

Real-world Safety and Efficacy of Indacaterol/Glycopyrronium in Japanese Patients with Chronic Obstructive Pulmonary Disease: A 52-week Post-marketing Surveillance
por: Kato, Chihiro, et al.
Publicado: (2021)

Early detection of gastric cancer after Helicobacter pylori eradication due to endoscopic surveillance
por: Sakitani, Kosuke, et al.
Publicado: (2018)

Reversible Posterior Leukoencephalopathy Syndrome Developing After Restart of Sunitinib Therapy for Metastatic Renal Cell Carcinoma
por: Fukui, Shinji, et al.
Publicado: (2016)

Metabolomic Analysis to Elucidate Mechanisms of Sunitinib Resistance in Renal Cell Carcinoma
por: Sato, Tomonori, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gpk0g80f0p2f14fnuiddrdbk8m